What are the causes of polycythemia and leukocytosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Causes of Polycythemia and Leukocytosis

Polycythemia and leukocytosis occurring together most commonly indicate polycythemia vera (PV), a myeloproliferative neoplasm characterized by JAK2 mutations (present in >90% of cases), though secondary causes must be systematically excluded before confirming this diagnosis.

Understanding the Clinical Context

When polycythemia presents with leukocytosis, this combination narrows the differential diagnosis significantly. The presence of both elevated red blood cells AND white blood cells suggests a clonal myeloproliferative process rather than isolated secondary erythrocytosis 1, 2.

Primary Cause: Polycythemia Vera

Polycythemia vera is the predominant cause when both conditions coexist. According to WHO 2008 criteria, PV diagnosis requires 3:

Major Criteria:

  • Hemoglobin ≥18.5 g/dL in men, ≥16.5 g/dL in women
  • Presence of JAK2 V617F mutation (found in >90% of PV patients) or JAK2 exon 12 mutation

Minor Criteria (need 1 with both major, or 2 with first major):

  • Bone marrow hypercellularity with trilineage growth (panmyelosis)
  • Serum erythropoietin below normal range
  • Endogenous erythroid colony formation in vitro

Key Clinical Features of PV:

  • Leukocytosis occurs in 49% of PV patients 2
  • Thrombocytosis in 53% 2
  • Splenomegaly (36%), pruritus (33%), erythromelalgia (5.3%) 2
  • Low serum erythropoietin levels (>90% specificity) 1

Critical pitfall: The PVSG diagnostic criteria (splenomegaly, leukocytosis, thrombocytosis, elevated leukocyte alkaline phosphatase) lack both sensitivity and specificity and should not be relied upon 1.

Secondary Causes of Polycythemia (Without Leukocytosis)

When polycythemia occurs WITHOUT leukocytosis, secondary causes become more likely 1:

Hypoxia-Driven (EPO-Mediated):

  • Chronic lung disease (COPD, pulmonary fibrosis)
  • Right-to-left cardiopulmonary shunts
  • High-altitude habitation
  • Carbon monoxide poisoning/chronic smoking
  • Sleep apnea and hypoventilation syndromes
  • Renal artery stenosis (localized hypoxia)
  • High oxygen-affinity hemoglobinopathies (congenital)

Hypoxia-Independent EPO Production:

  • Malignant tumors: Renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma, pheochromocytoma 1
  • Benign conditions: Uterine leiomyomas, renal cysts, meningioma
  • Chuvash polycythemia (von Hippel-Lindau gene mutation) 1

EPOR-Mediated:

  • Activating EPOR mutations (congenital, autosomal-dominant)
  • Exogenous erythropoietin or androgen use 1
  • Post-renal transplant erythrocytosis

Apparent Polycythemia:

  • Relative polycythemia from plasma volume contraction (dehydration, diuretics)
  • Extreme "high-normal" values 1

Causes of Leukocytosis (Independent of Polycythemia)

When leukocytosis occurs alone 4:

Nonmalignant Causes:

  • Infection (particularly bacterial)
  • Acute stressors: Surgery, trauma, exercise, emotional stress
  • Medications: Corticosteroids, lithium, beta-agonists
  • Smoking and obesity
  • Chronic inflammatory conditions
  • Asplenia

Malignant Causes:

  • Chronic myelogenous leukemia (CML) - BCR-ABL1 positive 3
  • Other myeloproliferative neoplasms: Essential thrombocythemia, primary myelofibrosis
  • Acute leukemias
  • Lymphoproliferative disorders

Diagnostic Algorithm for Combined Polycythemia and Leukocytosis

Step 1: Confirm elevated hemoglobin/hematocrit (>95th percentile for age/sex) AND elevated WBC count 1.

Step 2: Check serum erythropoietin level 1:

  • Low EPO: Highly suggestive of PV (>90% specificity)
  • Normal EPO: PV still possible (<70% sensitivity for low EPO)
  • High EPO: Consider secondary causes

Step 3: Test for JAK2 V617F mutation 3, 5:

  • Positive: Strongly supports PV diagnosis (>90% of cases)
  • Negative: Check JAK2 exon 12 mutations; if negative, consider other MPNs or secondary causes

Step 4: Perform bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis) 3, 1.

Step 5: Exclude secondary causes:

  • Oxygen saturation measurement
  • Chest X-ray for lung disease
  • Abdominal ultrasound for renal masses, splenomegaly
  • Sleep study if indicated
  • Smoking history

Critical distinction: If polycythemia is accompanied by leukocytosis or thrombocytosis, initial investigations should prioritize JAK2 mutation testing and serum EPO levels rather than extensive secondary cause workup 6.

Important Clinical Caveats

  • Iron deficiency can mask PV by lowering hemoglobin below diagnostic thresholds; look for microcytosis 1, 7
  • Red cell mass measurement is rarely needed in modern practice with JAK2 testing available 1, 5
  • JAK2 V617F is not specific to PV - found in ~50% of essential thrombocythemia and primary myelofibrosis cases 3
  • Leukocytosis at PV diagnosis is associated with higher thrombosis risk, particularly in patients <60 years 8
  • Thrombosis risk is highest with age >60 years or prior thrombotic history 2, 9

References

4
Research

Evaluation of Patients with Leukocytosis.

American family physician, 2015

8
Guideline

nccn guidelines insights: myeloproliferative neoplasms, version 2.2018.

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

Related Questions

What is the most important cause of polycythemia?
What is the indication for antiplatelet therapy in polycythemia vera?
Which blood test should be performed to exclude polycythemia vera?
In a patient with flu‑like symptoms, cough, and undocumented fever and chills who has an elevated hemoglobin and hematocrit, what is the most likely etiology and appropriate management?
What percentage of primary polycythemia cases are Polycythemia Vera (PV)?
After completing only the first cycle of R2 (rituximab and lenalidomide 10 mg), can the patient be switched to obinutuzumab while continuing lenalidomide 10 mg on a 21‑day‑on/7‑day‑off schedule?
Are Procto-Med HC (hydrocortisone acetate 2.5 % w/w and pramoxine hydrochloride 1 % w/w) and Analpram HC (hydrocortisone acetate 2.5 % w/w and pramoxine hydrochloride 1 % w/w) equivalent medications?
In a 9‑year‑old girl with attention‑deficit/hyperactivity disorder treated with Concerta (methylphenidate) 18 mg daily and generalized anxiety disorder who has persistent insomnia despite magnesium supplementation and sleep‑hygiene measures, what medication can be used to improve her sleep?
When is gastroprotective therapy indicated for patients taking nonsteroidal anti-inflammatory drugs (NSAIDs)?
Is there sufficient evidence to switch a patient who developed rituximab‑induced vasculitic hypersensitivity during the first cycle of rituximab + lenalidomide (10 mg) to obinutuzumab (obinutuzumab) plus lenalidomide?
What are the most common early side effects of escitalopram, their mechanisms, and how should they be treated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.